Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LysaKare serum potassium safety study in GEP-NET patients eligible for Lutathera
NL-OMON52585Phase 4Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lysine + arginine in Gastroenteropancreatic Carcinoid Tumor and Carcinoid Tumor (CT), sponsored by Advanced Accelerator Applications. Primary endpoint: Change in serum potassium concentration from baseline. Started Mar 2021; status: completed.
02
Drugs
lysine + arginine
03
Conditions
Gastroenteropancreatic Carcinoid TumorCarcinoid Tumor (CT)
Beyond the preview
Go deeper on NL-OMON52585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52585.